project . 2020 - 2021 . On going

Solnatide

Exploration of safety, tolerability and clinical efficacy of Solnatide IMP in patients infected with the 2019 new coronavirus
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 101003595 Call for proposal: H2020-SC1-PHE-CORONAVIRUS-2020
  • Funded under: H2020 | RIA Overall Budget: 1,626,020 EURFunder Contribution: 1,626,020 EUR
  • Status: On going
  • Start Date
    01 Apr 2020
    End Date
    31 Dec 2021
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
Clinical features of patients infected with the 2019-nCoV have revealed that these patients suffer from severe respiratory failure, and presence of a life-threatening pulmonary oedema (PPO). Approx. 30% of 2019-nCoV-patients further develop life-threatening Acute Respiratory Distress Syndrome (ARDS). Mortality rate of these patients is very high. Initiator and Scientific Coordinator of the project, APEPTICO, is a SME biotechnology company (EMEA/SME/012/09) developing peptide-based products targeting life-threatening pulmonary diseases, including oedematous respiratory failure, acute lung injury, primary graft dysfunction, high altitude pulmonary oedema and PHA t...
Description
Clinical features of patients infected with the 2019-nCoV have revealed that these patients suffer from severe respiratory failure, and presence of a life-threatening pulmonary oedema (PPO). Approx. 30% of 2019-nCoV-patients further develop life-threatening Acute Respiratory Distress Syndrome (ARDS). Mortality rate of these patients is very high. Initiator and Scientific Coordinator of the project, APEPTICO, is a SME biotechnology company (EMEA/SME/012/09) developing peptide-based products targeting life-threatening pulmonary diseases, including oedematous respiratory failure, acute lung injury, primary graft dysfunction, high altitude pulmonary oedema and PHA t...
Any information missing or wrong?Report an Issue